Failed Degradation of JunB Contributes to Overproduction of Type I Collagen and Development of Dermal Fibrosis in Patients With Systemic Sclerosis
暂无分享,去创建一个
D. Abraham | C. Denton | A. Holmes | George Bou-Gharios | M. Ponticos | Shiwen Xu | K. Khan | I. Papaioannou
[1] R. Farràs,et al. Regulation of GSK3β-FBXW7-JUNB Axis , 2013, Oncotarget.
[2] A. Pineda-Lucena,et al. GSK3-SCFFBXW7 targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase , 2013, Oncogene.
[3] Oliver Distler,et al. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. , 2012, Arthritis and rheumatism.
[4] J. Kriegsmann,et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis , 2012, Annals of the rheumatic diseases.
[5] M. Yaniv,et al. The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis , 2011, Annals of the rheumatic diseases.
[6] E. Wagner,et al. Targeting inflammation by modulating the Jun/AP-1 pathway , 2011, Annals of the rheumatic diseases.
[7] M. Fujimoto,et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. , 2010, Arthritis and rheumatism.
[8] D. Furst,et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. , 2009, Arthritis and rheumatism.
[9] D. Abraham,et al. JunB mediates enhancer/promoter activity of COL1A2 following TGF-β induction , 2009, Nucleic acids research.
[10] E. Wagner,et al. Targeting c-Jun and JunB proteins as potential anticancer cell therapy , 2008, Oncogene.
[11] Min Gao,et al. Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. , 2005, Molecular cell.
[12] D. Wells,et al. Cooperativity between Far Upstream Enhancer and Proximal Promoter Elements of the Human α2(I) Collagen (COL1A2) Gene Instructs Tissue Specificity in Transgenic Mice* , 2004, Journal of Biological Chemistry.
[13] M. Karin,et al. Jun Turnover Is Controlled Through JNK-Dependent Phosphorylation of the E3 Ligase Itch , 2004, Science.
[14] P. Nowell,et al. BCL2 and JUNB abnormalities in primary cutaneous lymphomas , 2004, The British journal of dermatology.
[15] D. Shegogue,et al. Mammalian Target of Rapamycin Positively Regulates Collagen Type I Production via a Phosphatidylinositol 3-Kinase-independent Pathway* , 2004, Journal of Biological Chemistry.
[16] D. Abraham,et al. Col1a2 enhancer regulates collagen activity during development and in adult tissue repair. , 2004, Matrix biology : journal of the International Society for Matrix Biology.
[17] E. Wagner,et al. Distinct involvement of the Jun‐N‐terminal kinase and NF‐κB pathways in the repression of the human COL1A2 gene by TNF‐α , 2002 .
[18] A. Szabowski,et al. Function of AP-1 target genes in mesenchymal-epithelial cross-talk in skin. , 2002, Biochemical pharmacology.
[19] D. Abraham,et al. Identification of the Key Regions within the Mouse Pro-α2(I) Collagen Gene Far-upstream Enhancer* , 2002, The Journal of Biological Chemistry.
[20] C. Denton,et al. Characterization of an Evolutionarily Conserved Far-upstream Enhancer in the Human α2(I) Collagen (COL1A2) Gene* , 2001, The Journal of Biological Chemistry.
[21] A. Szabowski,et al. Function and regulation of AP-1 subunits in skin physiology and pathology , 2001, Oncogene.
[22] P. Angel,et al. Induction of the AP-1 members c-Jun and JunB by TGF-β/Smad suppresses early Smad-driven gene activation , 2001, Oncogene.
[23] G. Angelini,et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. , 2000, Circulation.
[24] E. Wagner,et al. Control of cell cycle progression by c-Jun is p53 dependent. , 1999, Genes & development.
[25] D. Hanahan,et al. Transcription factors junB and c-jun are selectively up-regulated and functionally implicated in fibrosarcoma development. , 1992, Genes & development.
[26] M. Karin,et al. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. , 1991, Biochimica et biophysica acta.
[27] G. Karsenty,et al. Transcriptional control mechanisms for the expression of type I collagen genes. , 1991, Annals of the rheumatic diseases.
[28] D. Brenner,et al. Prolonged activation of jun and collagenase genes by tumour necrosis factor-α , 1989, Nature.
[29] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[30] James F. Fries,et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.
[31] S. Gay,et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. , 2010, Arthritis and rheumatism.